Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief Medical Officer

  Cytori Appoints Dr. Steven Kesten as Executive Vice President and Chief
  Medical Officer

Business Wire

SAN DIEGO -- February 26, 2013

Cytori Therapeutics (NASDAQ: CYTX) has appointed Steven Kesten, MD, as
Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten
will lead global clinical development operations and Cytori’s Medical Affairs
activities.

“Dr. Kesten is a seasoned physician executive with more than 30 years of
experience in medicine,” said Dr. Hedrick. “This experience includes
involvement in high profile clinical trials, leading medical affairs
activities, and navigating complex reimbursement environments. Dr. Kesten’s
contributions will further strengthen our clinical program, starting with our
cardiovascular business and extending to future therapeutic areas.”

Most recently Dr. Kesten served as Vice President and Chief Medical Officer at
Uptake Medical, where he oversaw the completion of the VAPOR trial and had
medical responsibility for the application that led to the CE Mark approval of
Uptake Medical’s device, InterVapor^®. He previously served for more than ten
years at Boehringer Ingelheim, most recently as the Vice President in Medicine
for Marketed Products for respiratory disease. During his tenure, Dr. Kesten
was responsible for the development and execution of multiple large-scale
clinical trials and took the medical lead in the global registration, branding
and reimbursement of the drug Spiriva^®, a $3 billion worldwide product for
chronic obstructive pulmonary disease. Dr. Kesten lived in Germany for three
years and is experienced in European regulatory affairs and reimbursement
strategies.

In addition, Dr. Kesten held the position of medical director of the Rush
Advanced Lung Disease and Lung Transplant Program at Rush Presbyterian St.
Luke’s Medical Center in Chicago. Dr. Kesten received his medical degree and
specialty training in internal medicine and pulmonary medicine at the
University of Toronto and has more than 160 peer-reviewed publications.

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution System product family. www.cytori.com

Contact:

Cytori Therapeutics
Investors
Tom Baker, +1-858-875-5258
tbaker@cytori.com
or
Media
Megan McCormick, +1-858-875-5279
mmccormick@cytori.com
 
Press spacebar to pause and continue. Press esc to stop.